BCMA CAR T cells

The winding path to success

Research output: Contribution to journalReview article

Abstract

Chimeric antigen receptor (CAR) T cells have been shown to successfully treat some hematopoietic malignancies. Recognition of a relevant target on malignant cells and the proper costimulatory molecule are essential for CAR T cell efficacy. In this issue of the JCI, Cohen et al. conducted an early phase trial to evaluate B cell maturation antigen–targeting (BCMA-targeting) CAR T cells in patients with refractory multiple myeloma. Patients who received the highest dose of BCMA-targeting CAR T cells in combination with lymphodepletion had the greatest response. The results of the study provide further support for the use of BCMA-targeting CAR T cells for myeloma, and reiterate the importance of space and cell dose for CAR T cell success.

Original languageEnglish (US)
Pages (from-to)2175-2177
Number of pages3
JournalJournal of Clinical Investigation
Volume129
Issue number6
DOIs
StatePublished - Jun 3 2019

Fingerprint

T-Cell Antigen Receptor
B-Lymphocytes
Hematologic Neoplasms
Multiple Myeloma
bis(3-bis(4-chlorophenyl)methyl-4-dimethylaminophenyl)amine

ASJC Scopus subject areas

  • Medicine(all)

Cite this

BCMA CAR T cells : The winding path to success. / Borrello, Ivan M; Imus, Philip.

In: Journal of Clinical Investigation, Vol. 129, No. 6, 03.06.2019, p. 2175-2177.

Research output: Contribution to journalReview article

@article{252202714b7c4068bd901b6cd27cfd68,
title = "BCMA CAR T cells: The winding path to success",
abstract = "Chimeric antigen receptor (CAR) T cells have been shown to successfully treat some hematopoietic malignancies. Recognition of a relevant target on malignant cells and the proper costimulatory molecule are essential for CAR T cell efficacy. In this issue of the JCI, Cohen et al. conducted an early phase trial to evaluate B cell maturation antigen–targeting (BCMA-targeting) CAR T cells in patients with refractory multiple myeloma. Patients who received the highest dose of BCMA-targeting CAR T cells in combination with lymphodepletion had the greatest response. The results of the study provide further support for the use of BCMA-targeting CAR T cells for myeloma, and reiterate the importance of space and cell dose for CAR T cell success.",
author = "Borrello, {Ivan M} and Philip Imus",
year = "2019",
month = "6",
day = "3",
doi = "10.1172/JCI128372",
language = "English (US)",
volume = "129",
pages = "2175--2177",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "6",

}

TY - JOUR

T1 - BCMA CAR T cells

T2 - The winding path to success

AU - Borrello, Ivan M

AU - Imus, Philip

PY - 2019/6/3

Y1 - 2019/6/3

N2 - Chimeric antigen receptor (CAR) T cells have been shown to successfully treat some hematopoietic malignancies. Recognition of a relevant target on malignant cells and the proper costimulatory molecule are essential for CAR T cell efficacy. In this issue of the JCI, Cohen et al. conducted an early phase trial to evaluate B cell maturation antigen–targeting (BCMA-targeting) CAR T cells in patients with refractory multiple myeloma. Patients who received the highest dose of BCMA-targeting CAR T cells in combination with lymphodepletion had the greatest response. The results of the study provide further support for the use of BCMA-targeting CAR T cells for myeloma, and reiterate the importance of space and cell dose for CAR T cell success.

AB - Chimeric antigen receptor (CAR) T cells have been shown to successfully treat some hematopoietic malignancies. Recognition of a relevant target on malignant cells and the proper costimulatory molecule are essential for CAR T cell efficacy. In this issue of the JCI, Cohen et al. conducted an early phase trial to evaluate B cell maturation antigen–targeting (BCMA-targeting) CAR T cells in patients with refractory multiple myeloma. Patients who received the highest dose of BCMA-targeting CAR T cells in combination with lymphodepletion had the greatest response. The results of the study provide further support for the use of BCMA-targeting CAR T cells for myeloma, and reiterate the importance of space and cell dose for CAR T cell success.

UR - http://www.scopus.com/inward/record.url?scp=85065436775&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065436775&partnerID=8YFLogxK

U2 - 10.1172/JCI128372

DO - 10.1172/JCI128372

M3 - Review article

VL - 129

SP - 2175

EP - 2177

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 6

ER -